Source: Brown A, et al. EASL 2015; Abstract P0771.Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6C-SCAPE Study: FeaturesC-SWIFT TrialDesign: Open-label, phase 2 trial to evaluate the efficacy and safety of elbasvir + grazoprevir + ribavirin versus elbasvir + grazoprevir versus grazoprevir + ribavirin in non-cirrhotic, treatment-naïve patients with GT 2, 4, 5, or 6 chronic hepatitis C infectionEntry Criteria - Chronic HCV GT2 (n=60), GT4 (n=20), GT5 (n=8), or GT6 (n=10)- 18 years or older- No prior HCV treatment- HCV RNA ≥10,000 IU/ml- No evidence of cirrhosisPrimary End-Point: SVR12